

Clinical Investigation Protocol

Simultaneous Measurement of Epicardial and Microvascular Resistance via Angiographic FLOW (SMARTFLOW) Study

Validation study of an AI-driven Angiogram-based Physiological Assessment

Protocol number: CSP-001
Revision: A
Date: 11 May 2026
Sponsor: AngioInsight, Inc.
Grant Giver: AngioInsight, Inc.
Principal Investigators: Todd C. Villines, MD and Carlos Collet, MD, PhD

Protocol approval page

We, the undersigned, have read and approved the protocol specified above and agree upon the contents:

Todd C. Villines, MD
Professor of Medicine (Cardiology)
University of Virginia, Charlottesville, USA
Co-Principal Investigator

Date

Carlos Collet, MD, PhD
Interventional Cardiologist
OLV Aalst
Co-Principal Investigator

Date

Table of Contents

<u>1. PROTOCOL SYNOPSIS</u>	<u>6</u>
<u>2. SCHEDULE OF ASSESSMENT</u>	<u>13</u>
<u>3. INTRODUCTION</u>	<u>15</u>
<u>4. THE ANGIOAI+ DEVICE</u>	<u>18</u>
4.1 PROPOSED INDICATIONS FOR USE	19
4.2 USES AND USE ENVIRONMENT:	19
4.3 CLINICAL WORKFLOW	19
4.4 IMAGE PROCESSING AND USER INTERFACE	20
4.5 USER INTERFACE AND OPERATION OF THE DEVICE	22
4.6 DASHBOARD REPORT.....	23
4.7 REPLAY OF INPUT DICOMS	25
4.8 FRACTIONAL FLOW RESERVE (FFR) AND 3D RECONSTRUCTION	26
4.9 VESSEL PROFILE	28
4.10 CORONARY MICROVASCULAR DISEASE (CMD)	29
4.11 ALGORITHM DEVELOPMENT	30
<u>5. STUDY DESIGN</u>	<u>31</u>
<u>6. ENDPOINTS</u>	<u>32</u>
6.1 PRIMARY ENDPOINTS	32
6.2 SECONDARY ENDPOINTS	33
6.3 EXPLORATORY ENDPOINTS:	34
<u>7. PATIENT SELECTION</u>	<u>34</u>
7.1 INCLUSION CRITERIA	36
<u>8. STUDY PROCEDURES</u>	<u>37</u>
8.1 PATIENT INFORMATION AND INFORMED CONSENT	37
8.2 BASELINE EVALUATION	38
8.3 CORONARY ANGIOGRAPHY	38
8.3.1 STANDARDIZED VIEW ACQUISITION ANGLES FOR ANGIOAI+.....	38
8.3.2 STANDARDIZED VIEW ACQUISITION ANGLES FOR CMD ASSESSMENT	39
8.4 INVASIVE DIAGNOSTIC PROCEDURE	39
8.5 INVASIVE EPICARDIAL ASSESSMENT	40
8.6 INVASIVE MICROVASCULAR ASSESSMENT.....	43
8.6.1 BOLUS THERMODILUTION MEASUREMENT	43

8.6.2	CONTINUOUS THERMODILUTION MEASUREMENT	44
8.7	CATH-LAB SYSTEM	47
	THE STUDY ALLOWS USE OF ANY OF THE FOLLOWING C-ARM SYSTEMS/DEVICES:.....	47
8.8	FFR DEVICES.....	47
	THE PRESSURE WIRE X (ABBOTT VASCULAR) WITH THE COROVENTIS SYSTEM WILL BE USED IN ALL PATIENTS.	47
8.9	CONTRAST INJECTION	47
9	<u>STATISTICAL DESIGN AND ANALYSIS</u>	47
9.1	ESTABLISHMENT OF ACCEPTABLE PERFORMANCE GOALS:.....	48
9.2	STATISTICAL ANALYSIS AND ANALYSIS SETS.....	51
9.3	HANDLING OF MISSING DATA.....	51
9.4	CONFIRMATORY ANALYSIS.....	52
9.4.3	MEASURES OF ACCURACY – QUALITATIVE TEST ASSESSMENT	52
9.4.4	UNDERLYING QUANTITATIVE TEST ASSESSMENT	52
9.5	SUBGROUP ANALYSIS	53
10	<u>SAFETY REPORTING</u>	54
10.1	SERIOUS ADVERSE EVENTS (SAES) DEFINITIONS.....	54
10.2	ANTICIPATED RISKS AND BENEFITS	55
10.2.1	ANTICIPATED BENEFITS FOR THE PATIENT	55
10.2.2	ANTICIPATED RISKS FOR THE PATIENT	55
10.3	REPORTING TO ETHICS COMMITTEE (EC)	55
10.4	RISK ANALYSIS.....	56
11	<u>QUALITY CONTROL AND QUALITY ASSURANCE.....</u>	58
11.1	COMPLIANCE TO STANDARDS AND REGULATIONS	58
11.2	ETHICS COMMITTEE (EC) / INSTITUTIONAL REVIEW BOARD (IRB) APPROVAL	59
11.3	DATA RECORDING	59
11.4	QUALITY ASSURANCE AND MONITORING.....	59
11.4.1	MONITORING ACTIVITIES	60
11.5	QUALITY ASSURANCE AND DATA MANAGEMENT	60
12	<u>ORGANISATION.....</u>	61
12.2	DATA COLLECTION AND QUALITY CONTROL	62
12.3	STEERING COMMITTEE	62
12.3.1	COMPOSITION & GOVERNANCE	62
12.4	DATA ACCESS & SCIENTIFIC INTEGRITY.....	62
12.4.1	DATA MANAGEMENT	63
12.5	STATISTICAL ANALYSIS.....	63
13	<u>DATA HANDLING AND RECORD KEEPING.....</u>	63
13.1	SOURCE DOCUMENTATION (SD).....	63
13.2	CASE REPORT FORM COMPLETION	64

13.3	RECORD RETENTION	64
13.4	INVESTIGATOR RECORD CUSTODY & TRANSFER	64
14	PUBLICATION POLICY.....	65
14.1	DATA ACCESS & PRINCIPAL INVESTIGATOR (PI) RIGHTS	65
14.2	AUTHORSHIP & REVIEW PROCESS	65
14.3	STEERING COMMITTEE REVIEW	66
15	INVESTIGATOR RESPONSIBILITIES.....	66
15.1	INVESTIGATOR RESPONSIBILITY/PERFORMANCE.....	66
15.2	REQUIRED DOCUMENTS	66
15.4	INFORMED CONSENT	67
15.5	PROTOCOL DEVIATION.....	67
15.6	AUDITS / INSPECTION.....	68
16	REFERENCES	68

Table of Figures

Figure 1. Structure of the coronary circulation.....	16
Figure 2. Angio AI+ Clinical Workflow	20
Figure 3 AngioAI+ Dashboard (Example)	21
Figure 4. Anatomical assessments of coronary artery stenosis using AngioAI+	21
Figure 5. Functional assessments of coronary arteries using AngioAI+	22
Figure 6. AngioAI+ module pipeline.....	22
Figure 7. Image Upload	23
Figure 8. AngioAI+ Dashboard: (top) LCA toggle selected; (bottom) RCA toggle selected	25
Figure 9. DICOM replay	25
Figure 10. LCA FFR Estimation Model	27
Figure 11. RCA FFR Estimation Module.....	27
Figure 12. PPG Output.....	28
Figure 13. Vessel diameter profile.....	29
Figure 14. CMD Assessment	30
Figure 15. Study epicardial and microvascular cohorts.....	35
Figure 16. Example of epicardial physiological assessment	42
Figure 17. Example of microvascular assessment with bolus thermodilution.....	44
Figure 18. Example of microvascular assessment with continuous thermodilution in resting (top) and hyperemic conditions (bottom).	46

1. PROTOCOL SYNOPSIS

Study title	Simultaneous Measurement of Epicardial and Microvascular Resistance via Angiographic Flow
Short title	SMARTFLOW
Prepared by	Todd C. Villines MD and Carlos Collet MD, PhD
Study phase	Pre-market
Patient population	Patients with acute or chronic coronary artery disease
Aims	To establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for: 1. Fractional flow reserve (FFR) 2. Detection of coronary microvascular disease (CMD)
Design	Prospective, single-arm, observational multicenter study of patients with suspected coronary artery disease (CAD) undergoing clinically indicated invasive coronary angiography with physiological assessment. The study is designed to evaluate performance of the AngioAI+ software using the subject's acquired imaging and ground truth data in a retrospective manner. As such, the investigational AngioAI+ device will not inform clinical decisions amid the study; subjects will follow standard of care (SoC) for their indicated reference procedures.
Study endpoint(s)	<u>Primary endpoints 1 - FFR:</u> Per-vessel diagnostic performance (i.e., sensitivity and specificity) of AngioAI+ FFR for identifying flow-limiting lesions, using measured FFR as the reference standard <u>Primary endpoints 2- CMD:</u> Diagnostic performance (i.e., sensitivity and specificity) of AngioAI+ for detecting CMD in patients with non-obstructive

CAD (NOCAD) using invasive coronary flow reserve (CFR) derived from continuous thermodilution as reference.

Secondary endpoints:

1. Agreement between continuously measured AngioAI+ FFR and invasive FFR.
 2. Agreement between continuously measured AngioAI+ pullback pressure gradients (PPG) and invasive PPG.
 3. Agreement between continuously measured AngioAI+ CFR and invasive CFR
 4. Diagnostic performance of AngioAI+ using resting angiograms for detecting CMD in patients with NOCAD using invasive CFR (<2.5) derived from continuous thermodilution as reference.
 5. Diagnostic performance of AngioAI+ for detecting CMD in patients with NOCAD using invasive CFR (< 2.5) derived from bolus thermodilution as reference.
 6. Diagnostic performance of AngioAI+ for detecting CMD in patients with NOCAD using invasive IMR (> 25) derived from bolus thermodilution.
 7. Diagnostic performance of AngioAI+ for detecting CMD in patients with NOCAD using invasive CFR (< 2.5) and IMR (> 25) derived from bolus thermodilution as reference.
 8. Negative predictive value of AngioAI+ for detecting CMD in patients with NOCAD compared with invasive CFR (< 2.5) derived from continuous thermodilution as reference.
 9. Negative predictive value of AngioAI+ for detecting CMD in patients with NOCAD compared with invasive
-

CFR (< 2.5) derived from bolus thermodilution as reference.

10. Negative predictive value of AngioAI+ for detecting CMD in patients with NOCAD compared with invasive CFR (< 2.5) and IMR (> 25) derived from bolus thermodilution as reference.
11. Agreement between AngioAI+ derived luminal dimensions (diameter stenosis, reference vessel diameter, and minimal lumen diameter) and quantitative coronary angiography (QCA) as reference.
12. Test reproducibility and repeatability of the AngioAI+ FFR and CMD outputs.
13. Device rejection rate (%). The ratio of produced AngioAI+ FFR & CMD values from all AngioAI+ measurements that were attempted.
14. Any adverse events from performing the image or invasive assessments.
15. Time for invasive FFR, thermodilution CMD assessment and time for performance of AngioAI+ FFR and CMD analyses

Clinical Sites	Approximately 24 clinical sites in the United States and Europe.
Investigational technology	AngioAI+ System (AngioInsight, Inc, USA)
Eligibility and Cohorts	Adult patients with acute or chronic coronary syndromes referred for invasive coronary angiography with clinically indicated physiologic assessment. Two prospective cohorts will be included:

1. Cohort 1. Patients with intermediate coronary artery stenosis (30-90% diameter stenosis) with clinically indicated FFR assessment.
2. Cohort 2. Symptomatic patients with NOCAD (<30% stenosis) with clinically indicated microvascular assessment.

Key exclusion criteria
Clinical Exclusion Criteria

1. Patients presenting with ST-elevation acute coronary syndrome
2. Prior myocardial infarction in the target vessel
3. Stent implantation in the target vessel within the last 12 months
4. Previous coronary artery bypass grafting (CABG)
5. Previous heart valve surgery
6. Previous heart transplantation
7. Moderate-to-severe valvular disease
8. Left ventricular ejection fraction (EF) $\leq 45\%$
9. Hemodynamic instability or cardiogenic shock

Angiographic Exclusion Criteria

1. Left main stenosis $\geq 50\%$
 2. Chronic total occlusion in target vessel
 3. CTO in a non-target vessel
 4. Less than thrombolysis in myocardial infarction (TIMI) 3 flow in target vessel
 5. Target vessel receiving collaterals
 6. Inadequate coronary angiographic images
 7. Ostial lesions
 8. Severe tortuosity
-